Neil Averitt commentary: New ideas wanted for assessing pharma deals
Washington, D.C. ( July 26, 2022) -- Both federal antitrust agencies are looking for new ideas to deepen their analysis of pharmaceutical mergers, and now they have the workshop to prove it....